Impact of neuropathy severity on hand function, strength, and dexterity in patients with oxaliplatin-induced peripheral neuropathy.
6 affiliations
- 1Department of Physiotherapy and Rehabilitation, Graduate School of Health Sciences, Acıbadem Mehmet Ali Aydınlar University, Kayışdağı Caddesi No:32, Ataşehi, Istanbul, 34752, Türkiye.
- 2Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Fenerbahçe University, Istanbul, Türkiye.
- 3Department of Radiation Oncology, Prof. Dr. Cemil Taşcıoğlu City Hospital, Istanbul, Türkiye.
- 4Department of Medical Oncology, Topkapı Liv Hospital, Istinye University, Istanbul, Türkiye.
- 5Department of Physiotherapy and Rehabilitation, Graduate School of Health Sciences, Acıbadem Mehmet Ali Aydınlar University, Kayışdağı Caddesi No:32, Ataşehi, Istanbul, 34752, Türkiye. [email protected].
- 6Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Acıbadem Mehmet Ali Aydınlar University, Istanbul, Türkiye. [email protected].
Abstract
Background
Oxaliplatin frequently causes chemotherapy-induced peripheral neuropathy (CIPN), including impaired hand dexterity; however, factors associated with dexterity impairment remain unclear. This study aimed to compare hand function, dexterity, strength, and pain according to neuropathy severity, and to identify factors associated with impaired hand dexterity.Methods
A total of 206 patients received oxaliplatin-based chemotherapy, of whom 102 (49.5%) developed CIPN and were included in this cross-sectional study. All participants were aged ≥ 40 years and had received at least three cycles of oxaliplatin-based chemotherapy at a tertiary research hospital. Neuropathy severity was classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events as Grade (I-III). Outcome measures included grip strength measured with a hand dynamometer, pinch strength assessed with a pinch meter, fine motor skills and hand dexterity evaluated using the Minnesota Manual Dexterity Test (MMDT) and Nine-Hole Peg Test (NHPT), hand function assessed using the Michigan Hand Outcomes Questionnaire (MHOQ), pain intensity measured with the PainDETECT Questionnaire, and CIPN symptoms evaluated using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20 (EORTC QLQ-CIPN20). Group comparisons were performed using one-way ANOVA or Kruskal-Wallis tests with Tukey or Dunn post-hoc analyses, respectively. Ordinal logistic regression (complementary log-log link) identified predictors of neuropathy severity, while multiple linear regression analyses assessed factors associated with hand dexterity.Results
Significant between-group differences were observed in grip and pinch strength, hand dexterity performance, MHOQ subparameters, CIPN20 scores, and PainDETECT scores (p < 0.05). Neuropathy severity was significantly associated with cumulative oxaliplatin dose and gender (p < 0.05), with higher cumulative doses increasing the risk of severe neuropathy. Regression analyses demonstrated that grip strength, gender, and CIPN20 motor scores were significant predictors of hand dexterity performance in both MMDT placing and turning models (p < 0.001). Lower grip strength and higher motor neuropathy scores were associated with poorer dexterity performance.Conclusion
Increasing neuropathy severity was associated with poorer hand function, reduced strength, and impaired manual dexterity. Cumulative oxaliplatin dose and sex were significant predictors of neuropathy severity, whereas grip strength and motor neuropathy symptoms were important determinants of hand dexterity performance.Trial registration
ClinicalTrials.gov NCT07203066, registered on 24 September 2025.
Related
- Baseline Peripheral Neuropathy Predicts Clinically Significant Neuropathy During Paclitaxel Treatment Following Oxaliplatin-based Chemotherapy.
- "It's Like a Marathon": A Qualitative Study of Symptom Burden and Adaptation Among Patients with Oxaliplatin-Induced Peripheral Neuropathy During Treatment.
- Emerging Therapeutic Targets in Oxaliplatin-Induced Acute Peripheral Neuropathy: Biochemical Protection by Organoselenium via Redox and Ionic Regulation.
- Zdhhc14 promotes pyroptosis in the dorsal root ganglion of oxaliplatin‐induced peripheral neuropathy mice by enhancing GBP5 palmitoylation and suppressing its ubiquitination
- Systemic Sclerosis Presenting With Long-Standing Peripheral Neuropathy and Delayed Multisystem Manifestations: A Case Report
BibTeX
@article{koseoglu2026impact,
title = {{Impact of neuropathy severity on hand function, strength, and dexterity in patients with oxaliplatin-induced peripheral neuropathy.}},
author = {Özge Köseoğlu and Selvi Dinçer and Necla Gürdal and Emir Çelik and Özlem Feyzioğlu},
journal = {BMC cancer},
year = {2026},
month = jul,
doi = {10.1186/s12885-026-16621-y},
url = {https://europepmc.org/article/MED/42958115},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Impact of neuropathy severity on hand function, strength, and dexterity in patients with oxaliplatin-induced peripheral neuropathy.
AU - Özge Köseoğlu
AU - Selvi Dinçer
AU - Necla Gürdal
AU - Emir Çelik
AU - Özlem Feyzioğlu
PY - 2026
DA - 2026/07/30
JO - BMC cancer
DO - 10.1186/s12885-026-16621-y
UR - https://europepmc.org/article/MED/42958115
AB - Background Oxaliplatin frequently causes chemotherapy-induced peripheral neuropathy (CIPN), including impaired hand dexterity; however, factors associated with dexterity impairment remain unclear. This study aimed to compare hand function, dexterity, strength, and pain according to neuropathy severity, and to identify factors associated with impaired hand dexterity.Methods A total of 206 patients received oxaliplatin-based chemotherapy, of whom 102 (49.5%) developed CIPN and were included in this cross-sectional study. All participants were aged ≥ 40 years and had received at least three cycles of oxaliplatin-based chemotherapy at a tertiary research hospital. Neuropathy severity was classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events as Grade (I-III). Outcome measures included grip strength measured with a hand dynamometer, pinch strength assessed with a pinch meter, fine motor skills and hand dexterity evaluated using the Minnesota Manual Dexterity Test (MMDT) and Nine-Hole Peg Test (NHPT), hand function assessed using the Michigan Hand Outcomes Questionnaire (MHOQ), pain intensity measured with the PainDETECT Questionnaire, and CIPN symptoms evaluated using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20 (EORTC QLQ-CIPN20). Group comparisons were performed using one-way ANOVA or Kruskal-Wallis tests with Tukey or Dunn post-hoc analyses, respectively. Ordinal logistic regression (complementary log-log link) identified predictors of neuropathy severity, while multiple linear regression analyses assessed factors associated with hand dexterity.Results Significant between-group differences were observed in grip and pinch strength, hand dexterity performance, MHOQ subparameters, CIPN20 scores, and PainDETECT scores (p < 0.05). Neuropathy severity was significantly associated with cumulative oxaliplatin dose and gender (p < 0.05), with higher cumulative doses increasing the risk of severe neuropathy. Regression analyses demonstrated that grip strength, gender, and CIPN20 motor scores were significant predictors of hand dexterity performance in both MMDT placing and turning models (p < 0.001). Lower grip strength and higher motor neuropathy scores were associated with poorer dexterity performance.Conclusion Increasing neuropathy severity was associated with poorer hand function, reduced strength, and impaired manual dexterity. Cumulative oxaliplatin dose and sex were significant predictors of neuropathy severity, whereas grip strength and motor neuropathy symptoms were important determinants of hand dexterity performance.Trial registration ClinicalTrials.gov NCT07203066, registered on 24 September 2025.
SN - 1471-2407
ER -